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ABSTRACT: Upregulation of cell adhesion molecules on endothelial
cells is a hallmark of inﬂammation and an early feature of several
neurological conditions. Here, we describe bimodal in vivo imaging of this
inﬂammatory event in the brain using functionalized micron-sized
particles of iron oxide. The particles were conjugated to anti-VCAM-1
antibodies and subsequently labeled with iodine-125. Radiolabeling of the
antibody-coated particles was straightforward and proceeded in high
radiochemical yields using commercially available iodination tubes. The corresponding contrast agent was evaluated in a rat
model of cerebral inﬂammation based on intracerebral injection of tumor necrosis factor alpha and a rat model of status
epilepticus. Biodistribution studies and phosphorimaging of cryosections were used to verify in vivo imaging data obtained with
single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI). The contrast agent showed
rapid and highly localized binding to the vasculature of inﬂamed brain tissue, and was eﬀectively cleared from the blood pool
within 2 min postinjection. Overall, the pattern of hypointensities observed with MRI was in good agreement with the
distribution of the contrast agent as determined with SPECT and phosphorimaging; however, conspicuous diﬀerences in the
signal intensities were observed. The results demonstrate that radiolabeled micron-sized particles of iron oxide enable multimodal
in vivo imaging with MRI and nuclear techniques, and highlight the value of validating diﬀerent imaging methods against one
another.
■ INTRODUCTION
Cerebral inﬂammation occurs as a result of infection or injury
and is known to be a feature of several neurological conditions
such as stroke,1 epilepsy,2 traumatic brain injury,3 brain
tumors,4,5 and Alzheimer’s disease.6 Molecular imaging is a
powerful tool which could help to determine which
inﬂammatory processes are beneﬁcial and which may be
detrimental to patient outcome. Furthermore, it could be used
for anti-inﬂammatory treatment monitoring and to identify
which patients might beneﬁt from such therapies.
Recently, imaging vascular cell adhesion molecule-1 (VCAM-
1) expression using micron-sized particles of iron oxide
(MPIOs) coupled with magnetic resonance imaging (MRI)
has shown to be a highly sensitive and speciﬁc method of
detecting and locating inﬂammation.7−14 The low constitutive
expression of VCAM-1 renders it an ideal target for molecular
imaging. It is expressed on the surface of endothelial cells and
therefore can be used to monitor pathology or therapies in the
brain without the need for contrast agents to cross the blood-
brain barrier (BBB). VCAM-1 mediates the rolling and
extravasation of leukocytes across the vascular endothelium.15
Furthermore, it is thought to play a key role in several
pathological conditions and may therefore provide a meaningful
biomarker of disease progression. For example, it has been
suggested that VCAM-1 can be hijacked by tumor cells to aid
adhesion to the vascular endothelium4 and may exacerbate the
initiation of seizures (ictogenesis) or the development of
epilepsy (epileptogenesis).16
The development of anti-VCAM-1 antibody coated MPIOs
as contrast agents (CAs) for MRI has been a major
technological advance as it enables neuroinﬂammation to be
detected and localized with high sensitivity and speciﬁcity.7,10
This has challenged the notion that MRI has insuﬃcient
sensitivity for molecular imaging in the brain, a domain
traditionally restricted to nuclear imaging modalities. MPIOs
provide marked contrast on MRI images, which can be
attributed to the sizable payload of iron which in turn results
in hypointense regions up to 50 times the physical diameter of
the particles.17 However, particle size also aﬀects the cellular
interactions, distribution, and clearance of CAs.
The exquisite performance of MPIOs as CAs for MRI is
intriguing as extensive eﬀorts over the past decade to develop
particle-derived nuclear imaging agents has met with limited
success, despite the superior detection limits of positron
emission tomography (PET) and single photon emission
computed tomography (SPECT).18−21 In order to gain further
insights into their properties as CAs, we have labeled VCAM-1
antibody coated MPIOs with iodine-125 (half-life 60 days).
The presence of radioactive iodine enables ex vivo biodis-
Received: March 31, 2015
Revised: July 27, 2015
Published: July 28, 2015
Article
pubs.acs.org/bc
© 2015 American Chemical Society 1542 DOI: 10.1021/acs.bioconjchem.5b00380
Bioconjugate Chem. 2015, 26, 1542−1549
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
tribution studies, measurement of blood clearance, and
validation of the observed MRI contrast with in vivo nuclear
imaging and ex vivo phosphorimaging. A further motivation for
this work was to determine whether MPIOs can be exploited as
radiotracers for biomodal imaging of molecular targets in the
vasculature. Herein, we report SPECT and MR imaging of
inﬂammation in a TNF-α model, and in the lithium−
pilocarpine model of Status Epilepticus (SE).
■ RESULTS
Radiochemistry. The radiolabeled contrast agent was
obtained directly from antibody coated MPIOs by incubation
with [125I]NaI in precoated iodogen tubes, and was isolated by
magnetic immobilization to give [125I]VCAM-MPIO in 85 ±
5% (n = 11) radiochemical yield. Iodine-125 was used due to
the ease of labeling, long half-life (60 days), and low energy
gamma emission (maximum energy 35 keV), which allowed in
vivo imaging data to be corroborated by ex vivo phosphorimag-
ing of brain sections.
Biodistribution Studies. In healthy rats, [125I]VCAM-
MPIO displayed rapid kinetics and was eﬀectively cleared from
the blood pool 2 min post-injection (Figure 1a). Within 10
min, the CA accumulated in the lungs (4.8 ± 1.3%ID/g),
spleen (3.4 ± 1.4%ID/g) and liver (1.5 ± 0.5%ID/g), with
negligible uptake in the brain (0.016 ± 0.005%ID/g) (Figure
1b and Supporting Information Table 1). The low radioactivity
levels in the bladder and thyroid, as seen by whole body
SPECT/CT 20−25 min post-injection (Figure 1c), suggest that
[125I]VCAM-MPIO remains largely intact after administration
in vivo. The discrepancies between the measured tissue
distribution of the contrast agent at 10 min p.i. and the
whole body SPECT image (20−25 min p.i.), can at least in part
be explained by the low density of lung tissue and the diﬀerent
units of quantiﬁcation; whereas organ distribution is normalized
to weight, SPECT provides a measure of radioactivity levels per
volume. However, the results may also reﬂect clearance from
the lungs to the liver and spleen over time.
Dose Optimization Studies in the TNF-α Induced
Model of Neuroinﬂammation. To allow sequential imaging
with SPECT/CT and MRI in individual animals, dose
optimization studies were performed in rats that were injected
with TNF-α in the right striatum to induce inﬂammation.
Following an initial study, 2 mg Fe/kg of [125I]VCAM-MPIO
appeared to be insuﬃcient to give discernible hypointensities
with MRI (Figure 2a). Hence, we used increasing doses of
VCAM-MPIO to determine a suitable concentration range for
MRI (Figure 2b,c). As expected, the MRI contrast eﬀect
appeared dependent on the amount VCAM-MPIO adminis-
tered, and was only apparent at the higher doses. At 5 mg Fe/
kg, there was a pronounced diﬀerence between TNF-α treated
animals, animals treated with saline, and TNF-α treated animals
that received the nonspeciﬁc CA (IgG-MPIO). As previously
reported,10 limited hypointense regions were observed in the
brains of animals from the two control groups (Figure 2d and
e). At the selected concentration of VCAM-MPIO (5 mg Fe/
kg), imaging with SPECT/CT showed localized binding of the
CA in the brains of TNF-α treated animals, consistent with
neuroinﬂammation, when using two diﬀerent radioactivity
levels (0.25 and 0.90 MBq per gram of body weight) (Figure
2f and g). As judged by the relative intensities of signals in the
brain and the extracranial regions, radioactivity levels of
approximately 0.25 MBq per gram of body weight appeared
optimal (Figure 2f), whereas a higher dose (0.90 MBq per gram
of body weight) resulted in a disproportionate increase in
background noise (Figure 2g). No brain uptake was observed in
the saline control group at either dose level (Figure 2h and i).
Five milligrams Fe/kg was suﬃcient for segmentation of
hypointense regions (Figure 2j−l). In the TNF-α group,
dynamic imaging with SPECT using 5 min frames from 20 to
45 min post-injection revealed that the binding of [125I]VCAM-
MPIO to the brain vasculature remained largely unchanged
over this period of time (SI Figure 1). For this reason, we
adopted a protocol with SPECT/CT commencing at 20 min
after administration of the CA, followed by imaging with MRI
45 min later, and subsequently, brains were extracted for ex vivo
phosphorimaging.
Qualitative Comparison of MRI, SPECT/CT, and
Phosphorimaging. To facilitate comparison of the data, the
MRI images were overlaid on the SPECT/CT images (Figure
3a−d). In TNF-α treated rats (n = 4), the hypointensities
present on MRI were in good agreement with the SPECT
signals in the brain, and also correlated well with phosphor-
imaging of cryosections from the site of TNF-α injection
(Figure 3f−h). However, the distribution of [125I]VCAM-
Figure 1. (a) Blood clearance and (b) biodistribution of 125I-labeled
VCAM-MPIO in healthy rats. For biodistribution studies, the animals
were euthanized 10 min post tracer administration and the results are
displayed as %ID/g (n = 3) ± SEM. (c) Whole body SPECT/CT
maximum intensity projection 20 min post CA administration (5 mg
Fe/kg, 0.25 MBq/g per gram, n = 1).
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MPIO in the cryosections appeared more widespread than was
evident from the in vivo imaging data obtained with MRI and
SPECT. Interestingly, in the saline treated control group,
phosphorimaging showed localized uptake of the CA at the
injection site, suggesting that the sham treatment also induced
local inﬂammation (Figure 3g). The low and homogeneous
radioactivity levels observed with phosphorimaging in brains
from animals that received [125I]IgG-MPIO conﬁrms that the
nonspeciﬁc binding of the CA is negligible (Figure 3h).
Quantitative Comparison of SPECT and MRI Data. To
enable quantitative comparison of the data obtained with
SPECT/CT and MRI, we determined the total signal from
[125I]VCAM-MPIO in the whole brain, as well as in the two
hemispheres. In the case of MRI, this was expressed as the
percentage contrast void across the brain volume. For SPECT,
the background was deﬁned as the average mean signal
intensity across the extracranial ﬁeld of view, and uptake of the
CA was expressed as the signal-to-background ratio in order to
normalize counts for body weight and the amount of
radioactivity that was administered. Importantly, injection of
TNF-α into the right striatum induces widespread inﬂamma-
tion that also aﬀects the left hemisphere, as can be seen by 3D
representation of MRI images (Figure 4a,b). Nevertheless,
comparison of the signal in the two brain hemispheres avoids
Figure 2. Representative coronal MRI and SPECT images
demonstrating binding of radiolabeled VCAM-MPIO at diﬀerent
doses of contrast agent (a−c) and levels of radioactivity (f−i). (a−c)
TNF-α group following administration of VCAM-MPIO: (a) 2 mg
Fe/kg, (b) 5 mg Fe/kg, and (c) 6 mg Fe/kg. The optimum dose of
iron oxide (5 mg Fe/kg) was assessed in two control groups: (d) saline
and (e) IgG. (f−i) SPECT/CT in the TNF-α and saline groups
administered with a lower and higher dose of radioactivity: (f) TNF-α
(0.25 MBq/g), (g) TNF-α (0.90 MBq/g), (h) Saline (0.25 MBq/g),
(i) Saline (0.71 MBq/g). (j−l) Illustration of quantiﬁcation procedure:
(j) brain extraction, (k) hypointense regions are segmented using local
thresholding, (l) segmented regions overlaid in red upon the original
MRI image, (m) blue crosshairs indicate the approximate location of
the coronal slices for the displayed MRI and SPECT/CT images. For
display purposes, SPECT images are thresholded at 40% of the 95th
percentile and linearly scaled between this value and the 95th
percentile.
Figure 3. Bimodal in vivo imaging and ex vivo phosphorimaging of
VCAM-1 expression. (a−d) Intracerebral TNF-α + [125I]VCAM-
MPIO (5 mg Fe/kg): (a) coronal MRI image, (b) coronal SPECT/
CT image, (c) co-registered MRI and CT image, (d) SPECT overlaid
on MRI image. (e) Illustration of the approximate location for coronal
sections. (f−h) Coronal phosphorimaging sections: (f) TNF-α, (g)
saline control, (h) IgG control.
Figure 4. 3D representation of CA binding and in vivo quantitation
using SPECT and MRI. 3D representation of CA binding (VCAM-
MPIO, 5 mg Fe/kg) based on in vivo MRI images for the (a) saline
control group and the (b) TNF-α treated group. Segmented
hypointense regions are shown in red, while the pink, green, and
blue areas indicate the whole brain, left, and right regions of interest
(respectively) used for quantiﬁcation. Quantiﬁcation of VCAM-MPIO
binding as assessed by (a) in vivo MRI and (b) in vivo SPECT.
Quantiﬁcation was carried out over the whole brain (red) as well as the
left (green) and right (blue) cerebral hemispheres. The saline group
received intracerebral saline injections followed by radiolabeled
VCAM-MPIO (5 mg Fe/kg, 0.25−0.9 MBq/g) (n = 3). The IgG
group received intracerebral TNF-α injections followed by radio-
labeled IgG-MPIO (5 mg Fe/kg, 0.25−0.9 MBq/g) (n = 3) and the
TNF-α group received intracerebral TNF-α injections followed by
radiolabeled VCAM-MPIO (5 mg Fe/kg, 0.25−0.9 MBq/g) (n = 4).
Abbreviations: LLeft, WBWhole brain, RRight.
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bias from manually deﬁning the regions of interest, and was
used in order to highlight diﬀerences in the data obtained with
MRI and SPECT. Quantitation with both MRI and SPECT
revealed higher CA binding in TNF-α treated animals as
compared to the two control groups, globally as well as in each
of the brain hemispheres (Figure 4c,d and SI Figure 2). In the
TNF-α treated animals, [125I]VCAM-MPIO localized predom-
inantly to the aﬀected (right) cerebral hemisphere (n = 4) as
assessed by both SPECT (p = 0.03) and MRI (p = 0.002).
While the SPECT and MRI data were in good overall
agreement, there are important diﬀerences in the results
obtained with the two modalities. In particular, MRI analysis
indicated more pronounced diﬀerence in CA uptake between
the left and right hemispheres in the TNF-α group than was
evident with SPECT, and the statistical signiﬁcance for the
group comparisons with MRI was substantially higher than for
SPECT. For instance, the diﬀerence in the group means when
comparing CA uptake in the right hemisphere reached a
signiﬁcance of p = 1 × 10−6 with MRI, but only p = 0.045 with
SPECT (Figure 4c,d). Unfortunately, the radioactivity levels
that were needed for imaging with SPECT/CT were too high
to allow quantiﬁcation of the CA in brain sections with
phosphorimaging.
Distribution of [125I]VCAM-MPIO within the Brain
Vasculature. To determine the distribution of [125I]VCAM-
MPIO within the brain vasculature, one TNF-α treated rat was
administered a reduced dose of [125I]VCAM-MPIO (3 mg Fe/
kg, 30 KBq/g). Phosphorimaging of brain cryosections (1 h
time point, Figure 5) revealed the CA to be distributed in a
pattern consistent with the hypointensities observed with MRI
(SI Figure 3) on slices both anterior and posterior to bregma.
While the iron oxide particles appear to be localized in the
vasculature, it is unclear whether they are on the arterial or
venous side of the circulation. Nevertheless, several large vessels
consistent with major arteries were identiﬁed: these include the
anterior striate arteries (astr), anterior choroidal artery (ach),
transverse hippocampal arteries (trhi), the supracollicular
network (scol),22 as well as the choroidal artery. The prominent
vessels which lie on the dorsal surface of both hemispheres also
contained high levels of the CA.
Imaging of Inﬂammation in the Lithium−Pilocarpine
Model of Status Epilepticus. We also assessed the potential
of [125I]VCAM-MPIO as a bimodal imaging agent to detect
inﬂammation in the lithium−pilocarpine model of Status
Epilepticus (SE). All pilocarpine treated animals progressed
to SE and displayed akinesia and facial automatizms. Tonic−
clonic seizures and SE were induced 40−50 min after
pilocarpine administration. The seizures were terminated after
90 min by administration of diazepam (10 mg/kg).
Approximately 20 h after induction of SE, [125I]VCAM-
MPIO (5 mg Fe/kg, 0.25 MBq/g) was administered and the
animals were imaged at the optimal time point as identiﬁed in
the study with TNF-α treated rats (vide supra). With SPECT/
CT (SEVCAM group, n = 3), highly localized uptake of the CA
was apparent in the cerebellum, cortex, brain stem, and
olfactory bulb (Figure 6a−c). With MRI, hypointensities were
mainly observed near the hippocampus and ventricles, but also
in the cerebral cortex and hypothalamic regions (Figure 6d).
Phosphorimaging of coronal brain cryosections conﬁrmed high
uptake of [125I]VCAM-MPIO in the cortex, hippocampus, and
hypothalamus (Figure 6e−g). As seen for the TNF-α treated
animals, [125I]VCAM-MPIO distributed predominantly to
larger blood vessels in the SEVCAM group. In the slices proximal
to the lambda, uptake of the CA was dominant at the choroid
plexus and within the vasculature, in particular in the middle
Figure 5. Phosphorimages of coronal brain sections (20 μm) from a
TNF-α treated animal administered [125I]VCAM-MPIO (3 mg/kg, 30
kBq/g). The distances of the brain sections shown from the bregma
are indicated in mm.
Figure 6. (a) Representative SPECT/CT images from a rat
administered [125I]VCAM-MPIO (5 mg Fe/kg, 0.25 MBq/g)
approximately 20 h after SE onset. Strong binding can be seen in
the cerebellum, cortex, brain stem, and olfactory bulb as viewed in the
sagittal (cerebellum and brain stem), coronal (cortex), and transversal
(olfactory bulb) slices. The (b) brain stem, (c) cerebellum, and
olfactory bulb are highlighted on an optical image of the rat brain.
High uptake of the CA was also observed with MRI (d) and
phosphorimaging (e) near the hippocampus and subfornical organ
(white arrows), as well as at the cortex (red arrows) and hypothalamus
(green arrows). (f) Optical image of the brain section shown in (e); P
= Posterior, A = anterior from the injection site. (g and h)
Phosphorimages of coronal brain sections (40 μm) from the (g)
SEVCAM group ([
125I]VCAM-MPIO: 5 mg Fe/kg, 0.25 MBq/g); (h)
SalineVCAM ([
125I]VCAM-MPIO: 5 mg Fe/kg, 0.07 MBg/g) and SEIgG
([125I]IgG-MPIO: 5 mg/kg, 0.07 MBq/g). For the SEvcam group, the
approximate locations of the sections displayed are given in mm. The
thresholding of the phosphorimages has been adjusted to account for
the amount of radioactivity administered.
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cerebral artery (Figure 6g). No uptake of the CA was evident in
brains from sham treated animals (SALINEVCAM, n = 3), nor in
control animals that received [125I]IgG-MPIO (SEIgG group, n =
3) (Figure 6h).
■ DISCUSSION
We have used iodine-125 labeled, VCAM-1 antibody coated,
micron-sized particles of iron oxide in two models of
neuroinﬂammation and have shown, for the ﬁrst time, its
potential as a bimodal imaging agent; conspicuity of the CA
was not only evident by MRI, but also seen with SPECT/CT
and phosphorimaging. Our kinetic studies revealed that
[125I]VCAM-MPIO binds rapidly to vasculature in inﬂamed
brain tissue and is quickly cleared from the blood pool. The
blood clearance rate of [125I]VCAM-MPIO was in good
agreement with previously reported data for other microsized
particles.23 This is signiﬁcant, as the rapid binding and clearance
makes microsized particles suitable for labeling with short-lived
positron emitters, such as gallium-68 and ﬂuorine-18, for
imaging of molecular targets in the vasculature with PET. It is
noteworthy that previous eﬀorts to develop particle-derived
radiotracers to date have focused almost exclusively on
nanoparticles,18−21 despite the need for exotic long-lived
radionuclides, such as copper-64 (half-life 12.7 h) and iodine-
124 (half-life 4.2 days), to match the prolonged circulation time
in the blood.24
Overall, there was good colocalization between the in vivo
SPECT and MRI images, and signiﬁcantly more contrast agent
was detected with both imaging techniques in rats treated with
TNF-α compared to the two control groups. However,
quantiﬁcation of the imaging data yielded marked diﬀerences
between the two techniques. This may, at least in part, be
explained by attenuation of the low energy γ rays emitted by
iodine-125 (35 keV) that was used for SPECT. In addition, the
nonlinear relationship between the local CA concentration and
contrast volume as assessed by MRI25 may have further
exacerbated the discrepancies in quantiﬁcation.
In the SE model, SPECT and MRI provided highly
complementary data with MRI hypointensities observed around
the hippocampus, the subfornical organ, and to a lesser extent
in the cerebral cortex. In contrast, SPECT/CT failed to detect
the binding of [125I]VCAM-MPIO in the hippocampus (Figure
6), likely due to attenuation, but revealed highly localized
signals in the cortex, cerebellum, brain stem, and olfactory bulb
(Figure 6a−d). Although the MRI data largely reﬂected the
distribution of [125I]VCAM-MPIO within the brain of SE
animals, comparison with SPECT and phosphorimaging
highlight the limitations of the MRI contrast eﬀect for imaging
in the outer regions of the brain. It is also evident that the
relationship between the volume of hypointense pixels within
the brain and the concentration of [125I]VCAM-MPIO is
nonlinear, which should be taken into account when using this
agent.
It is unclear to which degree the distribution of the CA is
dependent on cerebral blood ﬂow. Phosphorimaging of brain
sections showed that the CA localizes to large blood vessels,
which may imply a ﬂow component (Figure 5a). Although the
distribution to the larger vessels may be the result of a
signiﬁcant ﬁrst pass extraction, further studies are required to
determine how the interplay between blood ﬂow, extraction,
and VCAM-1 expression aﬀects the binding of VCAM-MPIO.
While it was outside the scope of this study to investigate the
pathology of the disease models in detail, it is worth noting that
the distribution pattern of [125I]VCAM-MPIO in the brains of
animals from the SE model was consistent with our previously
reported results,10 and demonstrates that the uptake reﬂects the
regions associated with inﬂammation.
In conclusion, we have developed a highly eﬃcient and
practical method to label VCAM-1 antibody coated iron oxide
microsized particles with iodine-125, and characterized the
contrast agent in two models of inﬂammation using SPECT/
CT, MRI, and phosphorimaging. Kinetic studies showed that
binding of [125I]VCAM-MPIO to the vasculature of inﬂamed
tissue remained relatively constant over a 20 min period and
that MPIOs are rapidly cleared from the blood pool. This
ensures high contrast, but is also a limitation in that the uptake
of the CA is likely to be inﬂuenced by regional blood ﬂow. The
pattern of hypointensities observed with MRI was consistent
with the distribution of [125I]VCAM-MPIO as observed using
phosphorimaging. Overall, this study provides proof of concept
that multimodal imaging of inﬂammation with both SPECT
and MRI is feasible. In the pilocarpine model of SE, MRI and
SPECT/CT proved highly complementary, with inﬂammation
detected in distinct brain regions by the two techniques,
demonstrating the value of validating diﬀerent imaging
methods against one another.
■ MATERIALS AND METHODS
Synthesis of VCAM-MPIO. Monoclonal antibodies speciﬁc
to rat VCAM-1 (MR106) (ebioscience, USA) were conjugated
to micron-sized particles of iron oxide (MPIOs, 1 μm diameter,
iron content: 26%, Invitrogen, Life Technologies, U.K.). In
general, 40 μg of antibody was reacted per mg of iron/MPIO
(Fe-MPIO) via a tosyl alkylation reaction following the
manufacturers’ guidelines and as previously reported. First,
MPIOs were washed. The beads in the original vial were
resuspended by vortexing for >30 s. The beads (5 mg of Fe per
kg of animal weight, 19.2 mg/kg MPIO, 38 μL) were then
placed in an eppendorf tube to which sodium borate buﬀer
solution (1000 μL, 0.1 M, pH 9.5) was added and vortexed for
>30 s. The eppendorf was placed next to a magnet (0.5 T,
nickel plated, K&J Magnetics Inc., USA) to immobilize the
particles, and the supernatant was removed with a Gilson
pipette (Gilson Scientiﬁc Ltd., U.K.). After removing the tube
from the magnet, to the washed beads was then added sodium
borate solution (415 μL, 0.1 M, pH 9.5) followed by the
antibodies (154 μg, 154 μL). Finally, ammonium sulfate
solution (138 μL, 3 M dissolved in 0.1 M sodium borate buﬀer
(100 mL, pH 9.4)) was added and the mixture was incubated
overnight at 37 °C with slow shaking to ensure the beads did
not settle during the incubation period. Following antibody
conjugation, a magnet was used to immobilize VCAM-MPIO.
The supernatant containing unbound antibodies was removed
and VCAM-MPIO was resuspended in heparinized PBS (0.1%,
100 μL).
Synthesis of Iodine-125 Labeled VCAM-MPIO.
[125I]NaI (>12.95 GBq/ml, 629 GBq/mg) (PerkinElmer,
USA) was purchased as a non-carrier-added solution in
reductant free 10−5 M aqueous sodium hydroxide solution
(pH 8−11). All other chemicals were purchased from Sigma-
Aldrich U.K. unless otherwise stated.
VCAM-MPIO (19.2 mg MPIO, 40 μL) was suspended in
heparinized phosphate-buﬀered saline (PBS) (100 μL, pH 7.4),
and then transferred into precoated iodogen tubes (Thermo
Fisher Scientiﬁc, USA). To this, [125I]NaI (30−120 MBq) was
added and the mixture was left to incubate at room temperature
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for 30 min. After this time, the radioactive mixture was
transferred into an eppendorf tube and radiolabeled VCAM-
MPIO ([125I]VCAM-MPIO) was puriﬁed using the magnetic
immobilization technique described above. The particles were
washed with PBS (1 mL) prior to their administration into rats.
Using this same protocol, [125I]IgG-MPIO was synthesized
using nonspeciﬁc control antibodies (Southern Biotech, U.K).
Animal Models. All animal procedures were carried out in
accordance with the UK Animals (Scientiﬁc Procedures) 1986
Act and institutional ethics regulations. Adult male Sprague−
Dawley rats (170−270 g) were obtained from the breeding
colony of the University College London (UCL) animal facility.
Neuroinﬂammation Model. Rats were anaesthetized using a
combination of isoﬂurane (1% in pure oxygen) and urethane
(1.5 g/kg, i.p.). TNF-α (300 ng, Life Technologies Ltd. U.K.)
in saline (5 μL) was injected into the right striatum
(coordinates from bregma: −0.5 mm anteroposterior, 3 mm
mediolateral, 4 mm dorsoventral from dura) using a Hamilton
syringe (Hamilton Company, USA) attached to a 31G needle.
Saline (5 μL) was administered in place of TNF-α for the
control group.
Lithium-Pilocarpine Model of Status Epilepticus (SE). Rats
were injected with lithium chloride (3 mg/kg, intraperitoneally
(i.p.)) 3 h prior to methyl scopolamine nitrate (5 mg/kg, i.p.)
administration. This was followed 30 min later by admin-
istration of pilocarpine hydrochloride (30 mg/kg, i.p.) in order
to induce SE (SEVCAM). Animals were behaviorally assessed and
the onset of SE was deﬁned as stage 3 on the Racine scale.
Diazepam (10 mg/kg, i.p., Hameln Pharmaceuticals, U.K.) was
administered 90 min after SE onset to terminate the seizure.
Further injections of diazepam were administered as required.
The control groups received saline in place of pilocarpine
hydrochloride.
Biological Evaluation of [125I]VCAM-MPIO. Unless
otherwise stated, rats were administrated [125I]VCAM-MPIO
or [125I]IgG-MPIO (5 mg Fe/kg, 0.25−0.9 MBq/g) in
heparinized phosphate-buﬀered saline (1 mL, pH 7.4) via a
cannula inserted into the right external jugular vein.
Blood Clearance and Biodistribution. Blood samples (n =
3) were collected via a jugular vein cannula at predetermined
time points (approximately: 85, 120 170, 230, 290 s) following
radiolabeled MPIO administration in rats anaesthetized by a
combination of isoﬂurane (1% in pure oxygen) and urethane
(1.5 g/kg). After each collection, the cannula was ﬂushed with
saline (1 mL) to remove residual radioactivity. For biodis-
tribution studies, radiolabeled MPIO (30−40 KBq/g) was
administered via the lateral tail vein (n = 3). Ten minutes after
tracer administration, the rats were anaesthetized with
isoﬂurane in pure oxygen. Blood was sampled through cardiac
puncture and the animals were sacriﬁced by cervical dislocation.
The organs of interest were then removed for gamma counting
(Wizard 2470, PerkinElmer, U.K.). The results are expressed as
% injected dose per gram of tissue ± SD.
In Vivo Imaging. Inﬂammation was induced by intrastriatal
injection of TNF-α as described above. Seven hours after the
intracerebral injection (vide supra), [125I]VCAM-MPIO or
[125I]IgG-MPIO was administered. Rats treated with Lithium-
Pilocarpine received [125I]VCAM-MPIO or [125I]IgG-MPIO
(SEVCAM and SEIgG) 20 h after the termination of seizures. For
the sham control group saline was administered instead of
pilocarpine (SALINEVCAM). For the duration of the in vivo
imaging experiments, isoﬂurane (1% in oxygen) was used to
maintain anesthesia in rats. A physiological monitoring system
(SA Instruments, USA) was used to monitor their respiration
rate and rectal temperature. Temperature was maintained at 37
± 0.5 °C using an air and water tubing warming system.
In vivo SPECT/CT (computed tomography) was performed
using a nanoSPECT system (Bioscan Inc. USA) approximately
20 min post contrast administration. A CT scan was conducted
with the following parameters: radial ﬁeld of view (FOV) =
40.5 mm2, axial FOV = 40.9 mm, exposure time per projection
= 1 s, 360 projections, and 55 KvP tube voltage, which resulted
in an acquisiton time of 6 min. Helical SPECT was performed
across the same FOV using 2.5 mm pinhole apertures with 20
projections and an exposure time of 15 s per projection. For
dynamic imaging, 5 scans were performed in succession
resulting in a total imaging time of 25 min. All SPECT/CT
images displayed are from the ﬁrst frames captured 20 min post
CA administration. To show the in vivo distribution of the CA,
a scan was performed across the entire FOV of the animal with
2.5 mm pinhole apertures and an acquisition time of 40 min.
In vivo MRI was performed immediately following SPECT/
CT imaging using a 9.4T horizontal bore scanner (Agilent
Technologies, USA). MRI was performed between 1 and 2 h
following administration of [125I]VCAM-MPIO and [125I]IgG-
MPIO. Iron oxide was detected using a 3D gradient echo
sequence (TR = 100 ms, TE = 11 ms, matrix = 192 × 192 ×
160, FOV = 25 × 25 × 25 mm3, acquisition time ≈ 51 min).
Phosphorimaging. Following in vivo imaging, the animals
were euthanized, their brains were removed and ﬁxed overnight
in 4% paraformaldehyde (PFA) in PBS (pH 7.4). The brains
were then cryoprotected overnight in sucrose solution and
sectioned coronally at 20 μm. Sectioning of the brain
commenced close to the bregma. The sections were then
mounted on poly(L-lysine) coated glass slides (VWR interna-
tional Ltd. U.K) which were subsequently exposed on
unmounted GP 20 × 25 cm2 phosphor screens (VWR
international LTD, U.K.) for 15 min. After this time, the
screens were scanned by a Typhoon 9410 Trio+ Phosphor-
imager (GE Healthcare, U.K.), (25 μm resolution, acquisition
time = 2 h 30 min) and the resulting images were processed by
ImageJ (NIH, USA).
As the radioactivity levels in the brain sections were above
the optimal range for phosphorimaging, one animal in the
TNF-α group was administered with a reduced dose of
[125I]VCAM-MPIO (3 mg Fe/kg, 30 kBq/g). The animal was
sacriﬁced 1 h post CA administration, and the brain was
removed and treated with PFA and sucrose as previously
described. Coronal sections (20 μm) of the brain were exposed
on a phosphor screen for 1 week, which was then scanned using
the parameters described above.
Optical Imaging. In order to correlate the observed signals
to particular brain regions, optical images of the sections used
for phosphorimaging were captured on a bright ﬁeld AxioSkop
2 system (Göttingen, Germany) at 5× magniﬁcation. The
images were processed using the tiling and stitching method
(Lundin M, 2004) on the Zeiss Axio Vision 4.8 software
(Imaging Associates, Germany).
Image Analysis. SPECT Reconstruction. SPECT images
were reconstructed using the HiSPECT software package using
the following parameters: smoothing = 45%, resolution = 67%,
number of iterations = 10. CT reconstruction was performed
using InVivoScope (InviCRO, USA). For display purposes, the
in vivo SPECT images are thresholded at 40% of the 95th
percentile and linearly scaled between this value and the 95th
percentile.
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MRI Quantiﬁcation of Contrast Agent Binding. MRI data
were processed in MATLAB 2013a (MathWorks, Natick, MA).
First, the data were zero-ﬁlled to 256 × 256 × 256 in k-space
prior to reconstruction to give a ﬁnal isotropic voxel size of 98
μm. Brain extraction was performed using a multiatlas
approach.26−28 Hypointensities caused by the presence of
iron oxide were segmented using adaptive thresholding in order
to take into account local variations in signal intensity. This was
achieved by subtracting the MRI volume from the volume
convolved with a three-dimensional Gaussian kernel of size 15
× 15 × 15 voxels and a σ of 15, followed by thresholding with
the same empirically determined threshold used across all data
sets. Regions of interest (ROIs) were deﬁned over the left or
right cerebral hemisphere surrounding the injection site. These
consisted of 30 consecutive slices (∼3 mm) anterior to and 30
consecutive slices posterior to the injection site (as indicated in
Figure 4a and b).
Coregistration. Coregistration of MRI and CT images was
performed in AMIRA (Visualization Sciences Group, Burling-
ton, MA) on the gradient images of the brain extracted MRI
magnitude data and the CT intensity images using normalized
correlation as the cost function.
SPECT Quantiﬁcation of Contrast Agent Binding. ROIs as
deﬁned on MRI images were propagated to the SPECT/CT
native space using the same transformation matrix. In this way,
identical ROIs were used for both the MRI and SPECT
analyses. Background signal intensity was deﬁned as the mean
signal intensity across all nonbrain tissue across the entire 3D
ﬁeld of view and CA binding was expressed as the signal-to-
background ratio to normalize counts for body weight and the
level of radioactivity that was administered.
Statistical Analysis. Statistical analysis was performed in
MATLAB. Group means were compared using one-way
ANOVA. Group means between the left and right hemispheres
were compared using one-tailed paired t tests. All error bars are
shown as mean ± standard error of the mean (SEM). Statistical
signiﬁcance was assigned at p < 0.05.
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